AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

LONDON (Reuters) -AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence ...

The AstraZeneca PLC ADR AZN advanced 1.52% to $69.55 Thursday, on what proved to be an all-around positive trading session ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Find insight on AstraZeneca, Hartalega and more in the latest Market Talks covering the health care sector.

AstraZeneca PLC ADR closed 22.59% below its 52-week high of $87.68, which the company achieved on August 30th.